Q1 Earnings Forecast for ImmunityBio Issued By HC Wainwright

ImmunityBio, Inc. (NASDAQ:IBRX) – Stock analysts at HC Wainwright dropped their Q1 2025 earnings per share (EPS) estimates for ImmunityBio in a research report issued on Wednesday, April 16th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($0.13) for the quarter, down from their prior estimate of ($0.12). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for ImmunityBio’s current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for ImmunityBio’s Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.12) EPS and FY2025 earnings at ($0.48) EPS.

Other equities analysts have also recently issued reports about the company. BTIG Research started coverage on ImmunityBio in a report on Friday, January 10th. They issued a “buy” rating and a $6.00 price target for the company. D. Boral Capital restated a “buy” rating and set a $30.00 target price on shares of ImmunityBio in a research report on Tuesday. One analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, ImmunityBio has an average rating of “Buy” and a consensus target price of $12.19.

ImmunityBio Trading Down 0.4 %

Shares of NASDAQ IBRX opened at $2.47 on Friday. ImmunityBio has a 52 week low of $2.28 and a 52 week high of $10.53. The stock has a market cap of $2.11 billion, a price-to-earnings ratio of -2.68 and a beta of 0.51. The company’s 50-day moving average price is $2.96 and its 200 day moving average price is $3.50.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings data on Monday, March 3rd. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.11. The firm had revenue of $7.55 million during the quarter, compared to analysts’ expectations of $8.74 million.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Courier Capital LLC boosted its holdings in ImmunityBio by 33.3% in the 1st quarter. Courier Capital LLC now owns 40,000 shares of the company’s stock worth $120,000 after acquiring an additional 10,000 shares during the period. Thrive Wealth Management LLC acquired a new stake in shares of ImmunityBio during the first quarter valued at about $30,000. Rhumbline Advisers grew its stake in ImmunityBio by 5.6% during the 1st quarter. Rhumbline Advisers now owns 219,360 shares of the company’s stock valued at $660,000 after purchasing an additional 11,573 shares in the last quarter. Collective Family Office LLC grew its position in shares of ImmunityBio by 17.3% during the first quarter. Collective Family Office LLC now owns 104,170 shares of the company’s stock worth $314,000 after buying an additional 15,340 shares in the last quarter. Finally, GF Fund Management CO. LTD. acquired a new position in ImmunityBio during the 4th quarter worth $37,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.